BioInnovation
VC Fund
Cambridge, United States
BioInnovation is a VC fund in Cambridge focused on Biotechnology and Therapeutics. BioInnovation LLC, based in Cambridge, Massachusetts, is an early stage life sciences investment and consulting firm. We make seed investments, act as institutional co-founders, and provide strategic and operational services. As investors and entrepreneurs ourselves, we understand the needs of early-stage companies, and the end-to-end requirementsneeded to start, grow and build successful ventures.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $66M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BioInnovation invests in
Stages BioInnovation invests in
Countries BioInnovation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 6 (67%)
- Therapeutics 4 (44%)
- Health Care 3 (33%)
- Medical 2 (22%)
- Wellness 1 (11%)
Stage
- Series A 4 (44%)
- Venture - Series Unknown 2 (22%)
- Seed 1 (11%)
- Series B 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Peter Parker
Founder and President
|
Founder and President | Total investments: 0 | Find email | |
Susie Harborth
Co-Founder
|
Co-Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $80M / Series B / Apr 01, 2020 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $8.2M / Series A / Jun 27, 2019 | ||
| Cereius is a pre-clinical stage company developing novel approaches to treating solid tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targetingagents. | $6.5M / Series A / Jul 25, 2018 | ||
| PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatmentat the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer. | Seed / Feb 23, 2018 | ||
| Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $58M / Series A / Jan 17, 2018 | ||
| Avexegen Therapeutics is an early stage development company working on novel and revolutionary therapies for the $10 Billion GI Market. | Venture - Series Unknown / Jan 01, 2018 | ||
| Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M / Series A / Apr 04, 2017 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $862.9K / Venture - Series Unknown / Jan 30, 2017 | ||
| See all 9 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BioInnovation invest in?
BioInnovation invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BioInnovation?
Public channels for BioInnovation include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioInnovation?
The team at BioInnovation includes Peter Parker (Founder and President) and Susie Harborth (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
